EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia

Haotian Ma, Zhifeng Yan, Runxia Gu, Yingxi Xu, Shaowei Qiu, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Min Wang, Jianxiang Wang

Cancer Immunology, Immunotherapy · 13.11.2024 · 74 (1)

DOI: 10.1007/s00262-024-03847-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 13.11.2024. Verfasst von Haotian Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blo…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Interleukin-3 Receptor alpha Subunit, Sialic Acid Binding Ig-like Lectin 3, Immunotherapy, Adoptive. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research & Development Program of China, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immunotherapy, such as chimeric antigen receptor T (CAR-T) cells targeting CD33 or CD123, has been well developed over the past decade for the treatment of acute myeloid leukemia (AML). However, the inability to sustain tumor-free survival and the possibility of relapse due to antigen loss have raised concerns. A dual targeting of CD33 and CD123 is needed for better outcomes. METHODS: Based on our previously constructed CD33 and CD123 monovalent CAR-T, Loop33 × 123 and Loop123 × 33 CAR-T were constructed with molecular cloning techniques. All CAR-T cells were generated by lentivirus transduction of T cells from healthy donors. Phenotype detection was evaluated on day 7 concerning activation, exhaustion, and subtype proportions. Coculture killing assays were conducted using various AML cell lines and primary AML cells. Degranulation and cytokine secretion levels were detected by flow cytometry. Cell-derived xenograft models were established using wild-type Molm 13 cell lines, or a mixture of Molm 13-KO33 and Molm 13-KO123 cells as an ideal model of immune escape. By monitoring body weight and survival of tumor-bearing mice, Loop33 × 123 and Loop123 × 33 CAR-T cells were further assessed for their efficacy in vivo. RESULTS: In vitro study, our results demonstrated that Loop33 × 123 CAR-T cells could efficiently eliminate AML cell lines and primary AML cells with elevated degranulation and cytokine secretion levels. Compared with our previously constructed monovalent CD33 or CD123 CAR-T cells, Loop33 × 123 CAR-T cells showed superior advantages in an immune escape model. In vivo studies further confirmed that Loop33 × 123 CAR-T cells could effectively prolong the survival of mice without significant toxicity. However, Loop123 × 33 CAR-T cells failed to show the same effects. Furthermore, Loop33 × 123 CAR-T cells efficiently circumvented potential immune escape, a challenge where monovalent CAR-T cells failed. CONCLUSIONS: Loop33 × 123 CAR-T targeting CD33 and CD123 could efficiently eliminate AML cells and prolong survival of tumor-bearing mice, while addressing the issue of immune escape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteInterleukin-3 Receptor alpha SubunitSialic Acid Binding Ig-like Lectin 3Immunotherapy, AdoptiveReceptors, Chimeric AntigenTumor EscapeXenograft Model Antitumor AssaysAnimalsHumansMiceT-LymphocytesCell Line, TumorMice, Inbred NODMice, SCIDFemale

Stichwörter der Autor:innen

AMLCD123CD33Chimeric antigen receptor

Substanzen

Interleukin-3 Receptor alpha SubunitSialic Acid Binding Ig-like Lectin 3CD33 protein, humanReceptors, Chimeric AntigenIL3RA protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematolo…
  • Tianjin Institutes of Health Science, Tianjin, 301617, China.
  • Tianjin Institutes of Health Science, Tianjin, 301617, China. wangjxm@ihcams.ac.cn.
  • Tianjin Institutes of Health Science, Tianjin, 301617, China. wangjx@ihcams.ac.cn.

Förderung

  • National Key Research & Development Program of China
  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Ma, H., Yan, Z., Gu, R., Xu, Y., Qiu, S., Xing, H., Tang, K., Tian, Z., Rao, Q., Wang, M., & Wang, J. (2024). Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia. Cancer Immunology, Immunotherapy, 74(1). https://doi.org/10.1007/s00262-024-03847-7

Vancouver

Ma H, Yan Z, Gu R, Xu Y, Qiu S, Xing H, et al. Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia. Cancer Immunology, Immunotherapy. 2024;74(1). doi:10.1007/s00262-024-03847-7

BibTeX
@article{Ma2024,
  author = {Ma, Haotian and Yan, Zhifeng and Gu, Runxia and Xu, Yingxi and Qiu, Shaowei and Xing, Haiyan and Tang, Kejing and Tian, Zheng and Rao, Qing and Wang, Min and Wang, Jianxiang},
  title = {Loop33 × 123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {74},
  number = {1},
  doi = {10.1007/s00262-024-03847-7}
}
Kostenlos starten →